Ebola virus can be effectively neutralized by antibody produced in natural human infection

Toshiaki Maruyama, Luis L. Rodriguez, Peter B. Jahrling, Anthony Sanchez, Ali S Khan, Stuart T. Nichol, C. J. Peters, Paul W.H.I. Parren, Dennis R. Burton

Research output: Contribution to journalArticle

212 Citations (Scopus)

Abstract

The activity of antibodies against filoviruses is poorly understood but has important consequences for vaccine design and passive prophylaxis. To investigate this activity, a panel of recombinant human monoclonal antibodies to Ebola virus antigens was isolated from phage display libraries constructed from RNA from donors who recovered from infection in the 1995 Ebola virus outbreak in Kikwit, Democratic Republic of Congo. Antibodies reactive with nucleoprotein (NP), envelope glycoprotein (GP), and secreted envelope glycoprotein (sGP) were characterized by immunofluorescence and radioimmunoprecipitation assays. Four antibodies reacting strongly with sGP and weakly with GP and two antibodies reacting with NP were not neutralizing. An antibody specific for GP neutralized Ebola virus to 50% at 0.4 μg/ml as the recombinant Fab fragment and to 50% at 0.3 μg/ml (90% at 2.6 μg/ml) as the corresponding whole immunoglobulin G1 molecule. The studies indicate that neutralizing antibodies are produced in infection by Ebola virus although probably at a relatively low frequency. The neutralizing antibody may be useful in vaccine design and as a prophylactic agent against Ebola virus infection.

Original languageEnglish (US)
Pages (from-to)6024-6030
Number of pages7
JournalJournal of virology
Volume73
Issue number7
StatePublished - Jun 23 1999

Fingerprint

Ebolavirus
glycoproteins
Glycoproteins
Ebola Hemorrhagic Fever
antibodies
Antibodies
Infection
nucleoproteins
Nucleoproteins
infection
Neutralizing Antibodies
neutralizing antibodies
Filoviridae
Vaccines
Radioimmunoprecipitation Assay
vaccines
Democratic Republic of the Congo
Immunoglobulin Fab Fragments
neutralization
bacteriophages

ASJC Scopus subject areas

  • Microbiology
  • Immunology
  • Insect Science
  • Virology

Cite this

Maruyama, T., Rodriguez, L. L., Jahrling, P. B., Sanchez, A., Khan, A. S., Nichol, S. T., ... Burton, D. R. (1999). Ebola virus can be effectively neutralized by antibody produced in natural human infection. Journal of virology, 73(7), 6024-6030.

Ebola virus can be effectively neutralized by antibody produced in natural human infection. / Maruyama, Toshiaki; Rodriguez, Luis L.; Jahrling, Peter B.; Sanchez, Anthony; Khan, Ali S; Nichol, Stuart T.; Peters, C. J.; Parren, Paul W.H.I.; Burton, Dennis R.

In: Journal of virology, Vol. 73, No. 7, 23.06.1999, p. 6024-6030.

Research output: Contribution to journalArticle

Maruyama, T, Rodriguez, LL, Jahrling, PB, Sanchez, A, Khan, AS, Nichol, ST, Peters, CJ, Parren, PWHI & Burton, DR 1999, 'Ebola virus can be effectively neutralized by antibody produced in natural human infection', Journal of virology, vol. 73, no. 7, pp. 6024-6030.
Maruyama T, Rodriguez LL, Jahrling PB, Sanchez A, Khan AS, Nichol ST et al. Ebola virus can be effectively neutralized by antibody produced in natural human infection. Journal of virology. 1999 Jun 23;73(7):6024-6030.
Maruyama, Toshiaki ; Rodriguez, Luis L. ; Jahrling, Peter B. ; Sanchez, Anthony ; Khan, Ali S ; Nichol, Stuart T. ; Peters, C. J. ; Parren, Paul W.H.I. ; Burton, Dennis R. / Ebola virus can be effectively neutralized by antibody produced in natural human infection. In: Journal of virology. 1999 ; Vol. 73, No. 7. pp. 6024-6030.
@article{6a929e14298d47df9e983eba18474ba5,
title = "Ebola virus can be effectively neutralized by antibody produced in natural human infection",
abstract = "The activity of antibodies against filoviruses is poorly understood but has important consequences for vaccine design and passive prophylaxis. To investigate this activity, a panel of recombinant human monoclonal antibodies to Ebola virus antigens was isolated from phage display libraries constructed from RNA from donors who recovered from infection in the 1995 Ebola virus outbreak in Kikwit, Democratic Republic of Congo. Antibodies reactive with nucleoprotein (NP), envelope glycoprotein (GP), and secreted envelope glycoprotein (sGP) were characterized by immunofluorescence and radioimmunoprecipitation assays. Four antibodies reacting strongly with sGP and weakly with GP and two antibodies reacting with NP were not neutralizing. An antibody specific for GP neutralized Ebola virus to 50{\%} at 0.4 μg/ml as the recombinant Fab fragment and to 50{\%} at 0.3 μg/ml (90{\%} at 2.6 μg/ml) as the corresponding whole immunoglobulin G1 molecule. The studies indicate that neutralizing antibodies are produced in infection by Ebola virus although probably at a relatively low frequency. The neutralizing antibody may be useful in vaccine design and as a prophylactic agent against Ebola virus infection.",
author = "Toshiaki Maruyama and Rodriguez, {Luis L.} and Jahrling, {Peter B.} and Anthony Sanchez and Khan, {Ali S} and Nichol, {Stuart T.} and Peters, {C. J.} and Parren, {Paul W.H.I.} and Burton, {Dennis R.}",
year = "1999",
month = "6",
day = "23",
language = "English (US)",
volume = "73",
pages = "6024--6030",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "7",

}

TY - JOUR

T1 - Ebola virus can be effectively neutralized by antibody produced in natural human infection

AU - Maruyama, Toshiaki

AU - Rodriguez, Luis L.

AU - Jahrling, Peter B.

AU - Sanchez, Anthony

AU - Khan, Ali S

AU - Nichol, Stuart T.

AU - Peters, C. J.

AU - Parren, Paul W.H.I.

AU - Burton, Dennis R.

PY - 1999/6/23

Y1 - 1999/6/23

N2 - The activity of antibodies against filoviruses is poorly understood but has important consequences for vaccine design and passive prophylaxis. To investigate this activity, a panel of recombinant human monoclonal antibodies to Ebola virus antigens was isolated from phage display libraries constructed from RNA from donors who recovered from infection in the 1995 Ebola virus outbreak in Kikwit, Democratic Republic of Congo. Antibodies reactive with nucleoprotein (NP), envelope glycoprotein (GP), and secreted envelope glycoprotein (sGP) were characterized by immunofluorescence and radioimmunoprecipitation assays. Four antibodies reacting strongly with sGP and weakly with GP and two antibodies reacting with NP were not neutralizing. An antibody specific for GP neutralized Ebola virus to 50% at 0.4 μg/ml as the recombinant Fab fragment and to 50% at 0.3 μg/ml (90% at 2.6 μg/ml) as the corresponding whole immunoglobulin G1 molecule. The studies indicate that neutralizing antibodies are produced in infection by Ebola virus although probably at a relatively low frequency. The neutralizing antibody may be useful in vaccine design and as a prophylactic agent against Ebola virus infection.

AB - The activity of antibodies against filoviruses is poorly understood but has important consequences for vaccine design and passive prophylaxis. To investigate this activity, a panel of recombinant human monoclonal antibodies to Ebola virus antigens was isolated from phage display libraries constructed from RNA from donors who recovered from infection in the 1995 Ebola virus outbreak in Kikwit, Democratic Republic of Congo. Antibodies reactive with nucleoprotein (NP), envelope glycoprotein (GP), and secreted envelope glycoprotein (sGP) were characterized by immunofluorescence and radioimmunoprecipitation assays. Four antibodies reacting strongly with sGP and weakly with GP and two antibodies reacting with NP were not neutralizing. An antibody specific for GP neutralized Ebola virus to 50% at 0.4 μg/ml as the recombinant Fab fragment and to 50% at 0.3 μg/ml (90% at 2.6 μg/ml) as the corresponding whole immunoglobulin G1 molecule. The studies indicate that neutralizing antibodies are produced in infection by Ebola virus although probably at a relatively low frequency. The neutralizing antibody may be useful in vaccine design and as a prophylactic agent against Ebola virus infection.

UR - http://www.scopus.com/inward/record.url?scp=0033039502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033039502&partnerID=8YFLogxK

M3 - Article

VL - 73

SP - 6024

EP - 6030

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 7

ER -